4886.T
ASKA Pharmaceutical Holdings Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 2,071.00
−0.10%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 71.1B | 71.1B | 64.1B | 62.8B | 60.5B |
| Cost of Revenue | 9.0B | 37.0B | 32.8B | 32.2B | 31.9B |
| Gross Profit | 8.6B | 34.1B | 31.3B | 30.7B | 28.6B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 7.2B | 28.3B | 26.0B | 24.2B | 23.5B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 7.2B | 28.3B | 26.0B | 24.2B | 23.5B |
| Cost and Expenses | 65.3B | 65.3B | 58.8B | 56.3B | 55.4B |
| Operating Income (EBIT) | 5.8B | 5.8B | 5.3B | 6.5B | 5.1B |
| Non-Operating | |||||
| Interest Income | 63.0M | 52.0M | 6.0M | 4.0M | — |
| Interest Expense | 51.0M | 222.0M | 51.0M | 40.0M | 50.0M |
| Net Interest Income | 12.0M | (170.0M) | (45.0M) | (36.0M) | (50.0M) |
| Other Non-Op Income/Expense | 141.0M | (168.0M) | (224.0M) | 22.0M | 125.0M |
| Non-Operating Income (excl Interest) | 219.0M | 688.0M | 392.0M | 410.0M | 433.0M |
| EBT (Pre-Tax Income) | 1.7B | 7.0B | 6.2B | 9.9B | 5.4B |
| Income Tax Expense | 372.0M | 1.4B | 1.1B | 2.3B | 1.1B |
| Bottom Line | |||||
| Net Income | 5.4B | 5.4B | 5.1B | 7.5B | 4.2B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 5.4B | 5.4B | 5.1B | 7.5B | 4.2B |
| Per Share | |||||
| Basic EPS | ¥191 | ¥191 | ¥180 | ¥267 | ¥150 |
| Diluted EPS | ¥191 | ¥191 | — | — | — |
| Revenue Per Share | ¥2,506 | ¥2,506 | ¥2,263 | ¥2,220 | ¥2,141 |
| Shares | |||||
| Basic Shares Outstanding | 28.4M | 28.4M | 28.3M | 28.3M | 28.2M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | 8.8B | 7.6B | 9.2B | 8.2B |
| D&A | — | 2.9B | 2.2B | 2.7B | 3.1B |
| EBIT | 5.8B | 5.8B | 5.3B | 6.5B | 5.1B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026